Page 89 - MemoriaEHD-Eng

www.ciberehd.org

• h e, L e, M ri, v J, B L, B JM .. Expression of
Most relevant erraezozaNoaCiasaQuerouJaNDaaNaLeset aL
SLC22A1 variants may affect the response of hepatocellular carcinoma and cholan-
scientific giocarcinoma to sorafenib.Hepatology. 2013 Sep;58(3):1065-73.

articles
• uriarte i, FerNáNDez-BarreNa Mg, MoNte MJ, Latasa Mu, ChaNg hC, Carotti s. Identifi-
cation of fibroblast growth factor 15 as a novel mediator of liver regeneration and

its application in the prevention of post-resection liver failure in mice.Gut. 2013
Jun;62(6):899-910.

• M JJ, h a, r ie, g-s e, g-B JM, p
ariNerNáNDezevueLtaoNzáLezaNChezoNzáLezuitragoérez
MJ. Mitochondrial genome depletion in human liver cells abolishes bile acid-induced
apoptosis: Role of the Akt/mTOR survival pathway and Bcl-2 family proteins.Free

Radic Biol Med. 2013 Apr 16;61C:218-228.

• vaQuero J, Briz o, herraez e, MuNtaNé J, MariN JJ. Activation of the nuclear receptor
FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against

genotoxic compounds.Biochim Biophys Acta. 2013 Oct;1833(10):2212-9.

• papaCLeovouLou g, aBu-hayyeh s, NiKoLopouLou e, Briz o, oWeN BM, NiKoLova v et aL.. Ma-

ternal cholestasis during pregnancy programs metabolic disease in offspring.J Clin
Invest. 2013 Jul 1;123(7):3172-81.

The Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM) is a
Highlights
multidisciplinary team directed by Dr. Jose Juan Garcia Marin, which is composed by
members of the Departments of Physiology and Pharmacology and of Biochemistry

and Molecular Biology, University of Salamanca and University Hospital of Salaman-
ca. The group belongs to the National Biomedical Research Centre for the Study of

Liver and Digestive Diseases (CIBERehd), Institute of Health Carlos III, and is part
of the Institute of Biomedical Research of Salamanca (IBASL).

Several of its components are members of the Spanish (AEEH) and European (EASL)

Associations for the Study of the Liver, the Spanish Society of Digestive Pathology
(EDPS), the Spanish Society of Biochemistry and Molecular Biology (SEBBM), the

Spanish (SECF), British (PS) and American (APS) Societies of Physiology, the Ame-

rican Society for Pharmacology and Experimental Therapeutics (ASPET) and the
Federation of American Societies for Experimental Biology (FASEB).

During the last 15 years the research group, recognized as Group of Excellence by
the Castilla and Leon Government, has been dedicated to the study of issues related

to Biochemistry, Physiology, Pathophysiology and Pharmacology of the liver.

The HEVEFARM coordinates a Doctoral Programme (Pathophysiology and Phar-
macology; http://www.usal.es/webusal/en/node/30186) and a University Master

(Master in Cellular and Molecular Pathophysiology and Pharmacology; http://www.

hevefarm.com/en).
The HEVEFARM has 4 patents (submitted plus obtained).

The HEVEFARM has participated in the development of a clinical guideline for the 13
20
management of patients with gestational cholestasis.
T
OR
The HEVEFARM regularly carries out analysis by HPLC-MS/MS of metabolomics (bile P
acids, flavonoids, steroid hormones, melatonin, sorafenib and other drugs) in biolo- RE
L
gical fluids, tissues and cell cultures for numerous international and national labo- A
ratories within and outside the CIBERehd.
NU
N
Bibliometric parameters of HEVEFARM: A
D /
Publications: >250 H
E
Impact Factor accumulated (last 5 years): >200 ER
IB
Cited Received: >2400 C

H Index: 29
89